Clinical outcomes are complex and often involve multiple systemic burdens. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological activation.
The platform can help align teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of scleroderma requires individualized development, typically including multidimensional management, such as drug therapy, rehabilitation, and regular follow-up visits. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely schemes according to changes in conditions. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of scleroderma. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.